Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'
Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'
On CNBC's "Mad Money Lightning Round," Jim Cramer said TORM plc (NASDAQ:TRMD) has a "remarkably high dividend yield. And as long as it has that dividend yield, the stock's going to stay up. But, when things start going bad, and they always do in this business, that yield's going to start going down."
Jim Cramer表示，在CNBC的“瘋狂金錢閃電回合”節目中，TORm plc (NASDAQ: TRMD) 的“股息收益率非常高。只要有這個股息收益率，股票就會保持上漲。但是，當事情開始變壞時，在這個業務中他們總是會這樣做，這種收益率就會開始下降。”
On July 23, Evercore ISI Group analyst Jonathan Chappell maintained TORM with an Outperform rating, while increasing the price target from $45 to $48.
7月23日，Evercore ISI Group 分析師Jonathan Chappell 維持對TORm的推薦評級，將股價目標上調至48美元，而之前爲45美元。
Cramer recommended buying Trane Technologies plc (NYSE:TT). "Hard to stop a Trane," he added.
Cramer 建議購買 Trane Technologies plc (NYSE: TT)。他補充說，“很難阻止“Trane”發展。”
Trane Technologies will report its second-quarter financial results on Wednesday, July 31. Analysts expect the company to report quarterly earnings at $3.08 per share, up from $2.68 per share in the year-ago period. Trane is projected to post quarterly revenue of $5.13 billion compared to $4.7 billion a year ago, according to data from Benzinga Pro.
Trane Technologies將於7月31日星期三公佈其第二季度業績。根據Benzinga Pro的數據，分析師預計該公司報告的季度每股收益爲3.08美元，高於去年同期的2.68美元。預計Trane將發佈營業收入51.3億，而去年同期爲47億。
When asked about Axsome Therapeutics, Inc. (NASDAQ:AXSM), he said, "This is central nervous system, CNS. If you can make a breakthrough in CNS, your stock will double. If not, it will just go down. That's a double or nothing stock right there."
當被問及Axsome Therapeutics, Inc. (NASDAQ: AXSM) 時，他說：“這是中樞神經系統，CNS。如果在CNS方面取得突破，你的股票會翻倍。否則，它就會下跌。那是一個賭一賠二的股票。”
On July 22, Needham analyst Ami Fadia initiated coverage on Axsome Therapeutics with a Buy rating and announced a price target of $130.
7月22日，Needham分析師Ami Fadia發起對Axsome Therapeutics的覆蓋，評級爲買入，並宣佈130美元的目標價。
The "Mad Money" host said SAP SE (NYSE:SAP) is "incredible" and recommended buying the stock. "I think that SAP is not done going higher," he added.
該“瘋狂金錢”主持人說，SAP SE（紐約證交所：SAP）“令人難以置信”，並建議購買該股票。他補充說，“我認爲SAP還沒有漲完。”
On July 22, SAP reported second-quarter earnings of 82 cents per share which missed the analyst consensus estimate of $1.19 per share. Quarterly sales came in at $8.92 billion which missed the analyst consensus estimate of $8.96 billion, representing an 8.81% increase over sales from the same period last year, according to data from Benzinga Pro.
7月22日，SAP報告了每股收益爲82美分的第二季度業績，低於分析師共識預估的每股收益1.19美元。根據Benzinga Pro的數據，季度銷售額爲892億美元，低於分析師共識預估的896億美元，同比增長8.81%。
Price Action:
價格行動：
- Torm shares gained 2% to settle at $40.45 on Tuesday.
- Trane shares rose 2.3% to settle at $344.96.
- Sap rose 7.1% to close at $214.76 during Tuesday's session.
- Axsome Therapeutics shares fell 0.5% to settle at $85.66 on Tuesday.
- Torm股價上漲2％，收於40.45美元。
- Trane股價上漲2.3％，收於344.96美元。
- SAP股價上漲7.1％，收於214.76美元。
- Axsome Therapeutics股價下跌0.5％，收於85.66美元。
- Best Buy, Kroger And 2 Other Stocks Insiders Are Selling
- 百思買、Kroger和其他2只股票的內部人士正在出售
譯文內容由第三人軟體翻譯。